| Literature DB >> 23025769 |
Michele Mussap1, Elisabetta Puxeddu, Patrizia Burrai, Antonio Noto, Francesco Cibecchini, Marcella Testa, Melania Puddu, Giovanni Ottonello, Angelica Dessì, Roberta Irmesi, Elisabetta Dalla Gassa, Claudia Fanni, Vassilios Fanos.
Abstract
Soluble CD14 subtype (sCD14-ST), also named presepsin, is a 13 kDa truncated form of soluble CD14 (sCD14), consisting of 64 amino acid residues. Systemic inflammation and sepsis are characterized by an early, significant increase in sCD14-ST presepsin blood concentration and thus, this small polypeptide has been proposed as a novel, reliable biomarker for the management of sepsis. We enrolled twenty-six consecutive non-septic preterm newborns with gestational age (GA) between 26 and 36 weeks) admitted to NICU after the first day of life for various severe diseases. sCD14-ST presepsin was measure on whole blood samples by a rapid commercial available chemiluminescent enzyme immunoassay (CLEIA) based on a non-competitive CLEIA. The mean sCD14-ST presepsin blood level in 26 preterm newborns was 643.1 ng/L, with a standard deviation (SD) of 303.8 ng/L; the median value was 578 ng/L. Our results clearly suggest no correlation between GA and sCD14-ST presepsin blood level between 26 and 36 weeks and thus it is reasonable to adopt a unique reference range for preterm newborns.Entities:
Mesh：
Substances：
Year: 2012 PMID： 23025769 DOI： 10.3109/14767058.2012.717462
Source DB: PubMed Journal: J Matern Fetal Neonatal Med ISSN： 1476-4954